United Therapeutics Co. (NASDAQ:UTHR) CEO Sells $1,141,380.00 in Stock

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction dated Monday, July 8th. The stock was sold at an average price of $317.05, for a total value of $1,141,380.00. Following the completion of the transaction, the chief executive officer now owns 130 shares in the company, valued at approximately $41,216.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

United Therapeutics Stock Down 1.6 %

NASDAQ:UTHR opened at $323.88 on Friday. The firm has a market capitalization of $14.37 billion, a PE ratio of 15.31, a price-to-earnings-growth ratio of 1.39 and a beta of 0.55. The stock has a 50 day moving average of $288.86 and a 200-day moving average of $249.00. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $330.00. The company has a current ratio of 3.77, a quick ratio of 3.64 and a debt-to-equity ratio of 0.04.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 EPS for the quarter, beating the consensus estimate of $5.63 by $0.54. The company had revenue of $677.70 million during the quarter, compared to analyst estimates of $620.31 million. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. The business’s revenue was up 33.7% compared to the same quarter last year. During the same period in the prior year, the company earned $4.86 earnings per share. Analysts predict that United Therapeutics Co. will post 24.73 EPS for the current year.

Hedge Funds Weigh In On United Therapeutics

Several institutional investors have recently made changes to their positions in UTHR. Norges Bank acquired a new stake in United Therapeutics in the 4th quarter valued at approximately $100,519,000. Swedbank AB acquired a new stake in United Therapeutics in the 1st quarter valued at approximately $97,316,000. Nordea Investment Management AB increased its position in United Therapeutics by 677.6% in the 1st quarter. Nordea Investment Management AB now owns 300,920 shares of the biotechnology company’s stock valued at $72,422,000 after acquiring an additional 262,222 shares during the period. Avidity Partners Management LP acquired a new stake in United Therapeutics in the 4th quarter valued at approximately $52,158,000. Finally, Canada Pension Plan Investment Board increased its position in United Therapeutics by 567.2% in the 1st quarter. Canada Pension Plan Investment Board now owns 180,800 shares of the biotechnology company’s stock valued at $41,533,000 after acquiring an additional 153,700 shares during the period. 94.08% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts recently commented on UTHR shares. UBS Group boosted their price target on United Therapeutics from $300.00 to $370.00 and gave the stock a “buy” rating in a research note on Monday. Morgan Stanley cut United Therapeutics from an “overweight” rating to an “equal weight” rating and boosted their price target for the stock from $310.00 to $321.00 in a research note on Thursday. StockNews.com cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, June 20th. Oppenheimer boosted their price objective on United Therapeutics from $375.00 to $400.00 and gave the company an “outperform” rating in a report on Thursday, May 2nd. Finally, Wells Fargo & Company boosted their price objective on United Therapeutics from $325.00 to $350.00 and gave the company an “overweight” rating in a report on Wednesday, June 12th. Two analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $321.55.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.